Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025

Core Viewpoint - Collegium Pharmaceutical's Executive Vice President and Chief Commercial Officer, Scott Dreyer, exercised options and sold 17,600 shares, reflecting a significant transaction value of approximately $847,800, while the company continues to show strong financial performance and stock growth [2][6][10]. Transaction Summary - On December 8, 2025, Scott Dreyer sold 17,600 shares for a total value of ~$847,800, which was 14.5% of his direct holdings at that time, reducing his ownership to 103,613 shares [2][3][6]. - The transaction was executed at a weighted average purchase price of $48.17, with the post-transaction value of his remaining shares estimated at ~$5.04 million based on the closing stock price of $48.66 on the same day [3][6]. Company Overview - Collegium Pharmaceutical has a market capitalization of $1.49 billion, employs 357 people, and reported a revenue of $757.07 million and a net income of $58.4 million for the trailing twelve months [5]. - The company specializes in innovative solutions for pain management and has a notable product for treating attention deficit hyperactivity disorder (ADHD) [5][8]. Stock Performance - In 2025, COLL shares surged nearly 60%, reaching an all-time high of $50.79 on December 29, indicating strong market performance [6][10]. - The company anticipates continued success in 2026, driven by its portfolio of ADHD and pain pharmaceuticals [10]. Insider Trading Context - The sale of shares by Dreyer was conducted under a Rule 10b5-1 trading plan, indicating that the timing of the transaction was prearranged rather than discretionary [7][9]. - The volume of shares sold in this transaction was above Dreyer's recent median selling pattern of 15,387 shares per trade [7].